Numeric aberrations of HER-2 and chromosome 17 detected by fluorescence in situ hybridization in urine-exfoliated cells from patients with urothelial carcinoma.

  title={Numeric aberrations of HER-2 and chromosome 17 detected by fluorescence in situ hybridization in urine-exfoliated cells from patients with urothelial carcinoma.},
  author={Takamitsu Inoue and Kazunari Sato and Norihiko Tsuchiya and Shinobu Matsuura and Masahiro Iinuma and Tomonori Habuchi and Tetsuro Kato},
  volume={64 3},
OBJECTIVES To elucidate the clinical significance of the HER-2 gene alterations in urine-exfoliated cells detected by fluorescence in situ hybridization (FISH) in patients with urothelial transitional cell carcinoma. METHODS The relative increase of HER-2 (RI-HER2) and gain of chromosome 17 (G-17) in urine-exfoliated cells were examined using DNA probes for HER-2 and the chromosome 17 centromere in 103 patients. In addition, FISH analysis was performed using corresponding paraffin-embedded… Expand
HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization
Increased HER2:CHR17 ratios demonstrate increased HER2 expression due to amplification in the majority of micropapillary carcinomas, suggesting that HER2-targeted therapy may be successful on the genomic level in patients with this disease. Expand
Expression of regulatory proteins and proliferative activity in relation to phenotypic characteristics of upper urothelial carcinoma.
This investigation showed that only negative regulatory proteins of the cell cycle, p53 and p16, were significantly associated in UUC, while proliferative marker Ki-67 was in relation to the key phenotypic characteristics of UUC in the best way. Expand
Prognostic and therapeutic role of HER2 expression in micropapillary carcinoma of the bladder
The aim of the present review was to summarize the existing evidence on HER2 status in MPBC, and to discuss its present and future utility in risk assessment and treatment choice of this uncommon, yet aggressive, disease. Expand
HER2 in solid tumors: more than 10 years under the microscope; where are we now?
This review will discuss the established knowledge and novel insights into the HER2 story, mainly focusing on breast, gastric and colorectal cancers, as well as providing a brief overview of salivary gland, bladder, ovarian and lung tumors. Expand
Molecular Markers in Upper Urothelial Carcinoma Associated to Balkan Endemic Nephropathy. Aristolochic Acid as the Major Risk Factor of the Worldwide Disease
The p53 pathway is identified as the specific cell cycle marker involved in BEN-associated UUC and the Ki-67 index was higher in control tumors with high-stage and solid growth than in BEN UUC. Expand
Targeted therapy in advanced bladder cancer: what have we learned?
The significance of genetic preselection in trial design as a method to optimize responses to these agents is discussed, thus, hopefully expanding the armamentarium of treatment options against this lethal disease. Expand


Numerical aberrations of chromosome 17 and the 9p21 locus are independent predictors of tumor recurrence in non-invasive transitional cell carcinoma of the urinary bladder.
It is suggested that evaluation of numerical aberrations of chromosome 17 and the 9p21 locus may represent a useful tool to assess tumor recurrence of pTa bladder carcinomas more accurately. Expand
Fluorescence in situ hybridization evaluation of c-erbB-2 gene amplification and chromosomal anomalies in bladder cancer.
  • J. Ohta, Y. Miyoshi, +5 authors Y. Kubota
  • Biology, Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2001
The results suggest that c-erbB-2 gene amplification, relative increase in c- Derbyshire 2 gene copy number, and gain of chromosome 17 may play important roles in the development and progression of bladder cancers. Expand
A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma.
The sensitivity of FISH for the detection of urothelial carcinoma is superior to that of cytology, and the specificity of Fish and cytology for uroclinical carcinoma are not significantly different. Expand
Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma.
Genetic alterations of chromosome 8 appear to accumulate in parallel with the progression of prostate carcinomas and AI of the c-myc gene, especially with loss of 8p22, appears to be associated with poor patient prognosis. Expand
Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder.
It is suggested that c-erbB-2 amplification and over-expression may provide a useful molecular marker in transitional cell carcinoma of the bladder and merits further investigation as a potential prognostic indicator. Expand
Heterogeneity of erbB-2 gene amplification in bladder cancer.
The arrangement of erbB-2 signals in clusters in all amplified cases suggests that erb B-2 amplification occurs intrachromosomally in bladder cancer. Expand
HER‐2 and TOP2A coamplification in urinary bladder cancer
The data suggest that Her‐2 amplifications are frequently linked to alterations of the TOP2A gene in bladder cancer and the anatomy of the 17q12‐q21 amplicon may be important for response to therapies targeting HER‐2 or TOP2a. Expand
Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract.
The results indicate that most multifocal low-grade superficial urothelial cancers are genetically stable despite their incidence of frequent recurrence, and genetic divergence occurs in a subset of patients, which supports the previous view that heterotopic spread of transformed progenitor cells and genetic Divergence occur after chromosome 9 alterations in most of low- grade superficial Urothelials cancers. Expand
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
The concept that the HER-2/neu gene may be involved in the pathogenesis of some human cancers, including breast and ovarian cancer, is supported. Expand
Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification.
Although the abrogation of normal p53 function may be one of the key steps to protooncogene amplification, the data indicate that the predisposition to gene amplification in urothelial cancers was not determined by the presence of p53 alteration alone. Expand